<DOC>
	<DOCNO>NCT02798172</DOCNO>
	<brief_summary>Objective : To observe effect alogliptin combine metformin pulmonary function obese patient type 2 diabetes inadequately control metformin monotherapy ( 500 mg , bid po , least 3 month ) , evaluate efficacy safety . Method : After 2-week screening period , adult patient ( age 36-72 year ) enter 4-week run-in/stabilization period . Then , patient randomly assign either intervention group ( n=55 ) control group ( n=50 ) 26 week . The patient control group give metformin ( 1,000 mg , bid po ) patient intervention group give metformin ( 500 mg , bid po ) combine alogliptin ( 25 mg , qd po ) . All patient receive counsel diet exercise nutritionist run-in treatment period . The primary endpoint between-group difference change pulmonary function parameter [ VC % , FVC % , FEV1 % , PEF % , MVV % , TLC % , FEV1/FVC % , DLCO % , DLCO/VA % ] pretherapy posttreatment . The secondary endpoint change baseline week 26 HbA1c , FPG , 2hPG , HOMA-IR , WC , BMI . The tertiary endpoint change baseline week 26 blood-fat ( TC , HDL-C , LDL-C , TG ) . The quartus endpoint change baseline week 26 SBP DBP . The fifth endpoint change baseline week 26 oxidative/antioxidative parameter ( ROS , MDA , SOD , GSH-PX ) . In addition , safety endpoint assess ( AEs , clinical laboratory test , vital sign , electrocardiographic reading ) .</brief_summary>
	<brief_title>The Effect Alogliptin Pulmonary Function Obese Patients With Type 2 Diabetes Inadequately Controlled Metformin Monotherapy</brief_title>
	<detailed_description>Alogliptin provide Takeda Chemical industry Ltd Japan , trade name : Nesina , 25 mg/tablet . Metformin provide Bristol Myers Squibb America , trade name : Glucophage , 500 mg/tablet . Research kit ROS , MDA , SOD , GSH-PX provide Nanjing Jiancheng Bioengineering Institute China . Research kit TC , HDL-C , HDL-C , TG provide provide Nanjing Jiancheng Bioengineering Institute China . The spirometer use pulmonary function test provide Jaska Corporation Japan , model number : HI-101</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 ) Aged 36 72 year either gender ; 2 ) BMI &gt; 28.0 kg/m2 , WC &gt; 90 cm ( male ) , WC &gt; 85 cm ( female ) ; 3 ) The patient diagnose T2DM serological outcome ( 7.0 % &lt; HbA1c &lt; 10.0 % ) reach therapeutic target oral metformin monotherapy ( 500 mg , bid po , â‰¥3 month prior screen ) ; 4 ) No smoke history , pulmonary disease pulmonary infection within fortnight ; 5 ) Did hepatopathy , nephropathy gastrointestinal disease ; 6 ) Likely good compliance able visit hospital periodic assessment . 1 ) T1DM , gestation lactation ; 2 ) Renal inadequacy ; 3 ) hypohepatia ; 4 ) Intensive care insulin treatment ; 5 ) Intolerance alogliptin metformin ; 6 ) Heart failure ; 7 ) Had receive antidiabetic agent ; 8 ) Antihypertensive drug control BP adequately severe uncontrolled hypertension ; 9 ) Cholesterollowering drug control bloodfat adequately ; 10 ) Use weight loss drug .</criteria>
	<gender>All</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>